

Clinical trials of Tinzaparin

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|---|
| tinzaparin vs control | | | |
| Jorgensen , 2002 n=99/106 follow-up: 38 days | Tinzaparin 3500 IU versus no prophylaxis | patients over 18 years of age with planned plaster cast on a lower extremity of at least 3 weeks | Parallel groups open, assessor-blinded |
| tinzaparin vs placebo | | | |
| Bergqvist [42] n=39/41 follow-up: | Tinzaparin 3500 anti-Xa units versus Placebo | - | Parallel groups Blind |
| Lassen , 1991 n=105/105 follow-up: 8-10 days | tinzaparin 50/kg x1 +elastic stockings versus Placebo+elastic stockings | Elective hip | double blind |
| tinzaparin vs unfractionated heparin | | | |
| Leizorovicz , 1991 n=861/429 | Tinzaparin 2500 and 3500 anti Xa units versus UFH 10 000 units | Abdominothoracic and gynaecological surgery | Blind |

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in elective hip replacement at <http://www.trialresultscenter.org/go-Q39>
- antithrombotics for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q92>
- heparin (UFH or LMWH) for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q189>
- LMWH for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q190>
- heparin (UFH or LMWH) for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q195>
- LMWH for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q196>
- antithrombotics for thrombosis prevention in patients with immobilization of the lower extremities at <http://www.trialresultscenter.org/go-Q405>

References

Jorgensen, 2002:

Jrgensen PS, Warming T, Hansen K, Paltved C, Vibeke Berg H, Jensen R, Kirchoff-Jensen R, Kjaer L, Kerbouche N, Leth-Espensen P, Narvestad E, Rasmussen SW, Sloth C, Trholm C, Wille-Jrgensen P Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study. *Thromb Res* 2002;105:477-80 [[12091045](#)]

Bergqvist [42], :

Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungstrm KG, Mtzsch T, Trngren S Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. *Vasa* 1996;25:156-60 [[8659218](#)]

Lassen, 1991:

Lassen MR, Borris LC, Christiansen HM, Boll KL, Eiskjaer SP, Nielsen BW, Schtt P, Olsen AD, Rodenberg JC, Lucht U Prevention of thromboembolism in 190 hip arthroplasties. Comparison of LMW heparin and placebo. *Acta Orthop Scand* 1991;62:33-8 [[1848385](#)]

Leizorovicz, 1991:

2 venous thrombosis

| Trial | Treatments | Patients | Trials design and methods |
|--|--|--|---|
| Tinzaparin vs acenocoumarol | | | |
| Romera , 2009 n=119/122 follow-up: 12 months | tinzaparin SC 175 IU anti-Xa per kg once daily for 6 months versus acenocoumarol for target INR 2-3 for 6 months after initial LMWH (until INR 2-3) | patients with symptomatic proximal DVT of the lowerlimbs confirmed by compression duplex ultrasound scan | Parallel groups open Spain |
| tinzaparin vs dalteparin | | | |
| Wells (subgroup) , 2005 n=NA follow-up: 3 months | Tinzaparin 175 IU/kg SQ daily (warfarin started simultaneously and continued for 90 days) versus dalteparin 200 IU/kg daily for at least 5 days ((warfarin started simultaneously and continued for 90 days) | study subgroup of patients with cancer treated for upper or lower extremity DVT or PE in the outpatient setting | Parallel groups outcome assessment blinded |
| extended tinzaparin vs standard treatment | | | |
| Hull , 2006 n=NA follow-up: 3 months | Tinzaparin 175 antiXa/kg SQ daily for 12 weeks versus UFH for 5 days followed by vitamin K antagonist (target INR 2-3) for 12 weeks | patients with cancer (solid or hematological) with proximal DVT with or without PE and with a minimum life expectancy of 3 months imag | Parallel groups outcome assessment blinded |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|---------------------------|
| Tinzaparin vs warfarin | | | |
| Hull , 2002 n=369/368 follow-up: 9 mo | LMWH, 175 IU/kg qd followed by Tinzaparin 175 IU/kg qd versus UFH 5 d, followed by UFH therapeutic APTT followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography/compression ultrasonography | open |
| Tinzaparin vs unfractionated heparin | | | |
| Hull et al , 1992 n=213/219 follow-up: 3 Months | Tinzaparin Subcutaneous once daily for >= Days, 175 U/kg BID versus unfractionated heparin intravenous APPTx2-3 | - | |

More details and results :

- antithrombotics for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q101>
- antithrombotics for venous thrombosis in patients with cancer at <http://www.trialresultscenter.org/go-Q103>
- LMWH for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q203>
- heparin (UFH or LMWH) for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q204>

References

Romera, 2009:

Romera A, Cairols MA, Vila-Coll R, Mart X, Colom E, Bonell A, Lapedra O A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. *Eur J Vasc Endovasc Surg* 2009;37:349-56 [19121589]

Wells (subgroup), 2005:

Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, Morrow B, Gray L, O'Rourke K, Wells G, Kovacs J, Kovacs MJ A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. *Arch Intern Med* 2005;165:733-8 [15824291]

Hull, 2006:

Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. *Am J Med* 2006;119:1062-72 [17145251]

Hull, 2002:

Hull RD, Pineo GF, Mah AF, et al, for the LITE Study A randomized trial evaluating long-term lowmolecular- weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract].582258 *Blood* 2002; 100:148a

Hull et al , 1992:

Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992 Apr 9;326:975-82 [[1545850](#)]

3 pulmonary embolism

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---|
| Tinzaparin vs unfractionated heparin | | | |
| ACTSG (Hull) sub-group , 1992 n=97/103 follow-up: 3mo | Tinzaparin, 175 IU/kg once daily, 6 days versus Unfractionated heparin: bolus 5000 IU, infusion 29 76040 320 IU/d | patients with objectively documented PE and underlying proximal deep vein thrombosi | Parallel groups double blind US, Canada |
| THESEE , 1997 n=301/307 follow-up: 3 mo | Tinzaparin, 175 IU/kg once daily, 5 days versus Unfractionated heparin: bolus 50 IU/kg, infusion 500 IU/kg per day | patients with symptomatic pulmonary embolism | Parallel groups open |
| Campbell , 1998 n=6/10 follow-up: 3 mo | Tinzaparin, 175 IU/kg once daily, 5 days versus Unfractionated heparin: bolus 5000 IU, infusion 1400 IU/h | Symptomatic PE | Parallel groups open |

More details and results :

- antithrombotics for pulmonary embolism in all type of patients at <http://www.trialresultscenter.org/go-Q102>

References

ACTSG (Hull) sub-group, 1992:

Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82 [[1545850](#)]

Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160:229-36 [[10647762](#)]

THESEE, 1997:

Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-9 [[9278462](#)]

Campbell, 1998:

Campbell IA, Yeoh J, Medlicott S.p, imag Duration of hospital stay in patients with pulmonary venous thromboembolism: a randomised comparison of unfractionated heparin versus low molecular weight heparin [Abstract] Thorax. 1998;53: 254

Entry terms: tinzaparin, tinzaparin, tinzaparin sodium, Innohep, warfarin